For instance, EGFR T790M mutation, which frequently occurs in 50%-60% of NSCLC patients who failed to EGFR-TKIs, impairs binding between first-/second-generation EGFR-TKIs and mutated EGFR.9 Osimertinib is a third-generation EGFR-TKI for treating NSCLC with EGFR T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.